UPDATE: Bionor Pharma Announces That the Combination of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV

OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA ( OSLO : BIONOR )

  • Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
  • Increase in CD4 count in both treatment groups notably in Vacc-4x + Revlimid group
  • Qualitative immune response analyses support the quantitative findings

Bionor Pharma ASA ( OSLO : BIONOR ) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the "Boost & Kill" study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment).

Bionor Pharma CEO Dr. Anker Lundemose commented, "We are encouraged by today's results with data demonstrating that the effects of Vacc-4x can be boosted by lenalidomide. This gives the option to add the 'Boost & Kill' to our current 'Kick & Kill' development strategy towards achieving a functional cure for HIV." 

The study's principal objective was to assess the combination of Vacc-4x + Revlimid in people living with HIV on ART but who have not regained a healthy CD4 level. Twenty four patients were randomized into two groups where one group received Vacc-4x + placebo and one group received Vacc-4x + Revlimid. Patients received six cycles of Vacc-4x vaccination with Revlimid or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26 (study end). 

CD4 counts, the key primary efficacy endpoint, increased in both groups. The largest increase was in the Vacc-4x + Revlimid group where CD4 count increased by 30% (p=0.009) from baseline. In the Vacc-4x + placebo group the CD4 count increased with 17% (p=0.10). However, this was an exploratory study, with a limited number of patients and no statistical difference was observed between the two groups.

The three other primary endpoints investigating immune response were T-cell response to Vacc-4x, antibody titer to Vacc-4x peptides and p24, and assessment of antibody titers to a commonly used tetanus toxoid. These immune markers supported the quantitative findings of the CD4 cells.

Only one serious adverse event was observed and deemed unrelated to treatment and overall both Vacc-4x and the combination treatment of Vacc-4x + Revlimid were safe and well tolerated.

"Study results announced today point to a novel step in the clinical research of a functional cure for HIV infection and these findings deserve to be further studied and confirmed as a part of a larger clinical trial," said Prof. Dr. Jan Van Lunzen University of Hamburg, Principal Investigator of the study.

"This trial demonstrated that Revlimid combined with Vacc-4x in people living with HIV is well tolerated. The results of this trial confirm our hypothesis that Revlimid may enhance the effects of Vacc-4x," said Jerome B. Zeldis MD, PhD, CMO Celgene Inc, CEO Celgene Global Health and Bionor Pharma ASA Board member.

Full data analysis is ongoing and will be submitted to a future major HIV medical conference. Furthermore the results will be discussed with FDA and EMA. The study is a collaboration between Celgene Corp ( NASDAQ : CELG ) and Bionor Pharma. Bionor Pharma has been the study sponsor and Celgene has co-funded the trial and supplied lenalidomide. This study, an important outcome of this collaboration, will be further discussed and analysed by the companies.

About the Trial The Phase I/II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid (lenalidomide) versus Vacc-4x with an initial open label dose escalation assessment of lenalidomide in HIV infected subjects on antiretroviral therapy, ART (SOC HIV treatment). Part A, the Phase I part of the trial, was an open label dose escalation assessment of lenalidomide, showed that all three doses tested were well tolerated, and the highest dose has been chosen for Part B of the study. Part B was a double-blinded placebo controlled parallel design, multicenter study. Both parts were in HIV infected subjects who are on ART but have not fully regained a healthy CD4 level (CD4 counts > 200x10 6 /mL and < 500x10 6 /mL. The trial was conducted in four centers in Germany.

The primary objective of this study is in Part A to establish the maximum tolerated dose of lenalidomide and in Part B to evaluate the immunomodulatory effect of lenalidomide under immunization with Vacc-4x (Vacc-4x + lenalidomide versus Vacc-4x + placebo) on CD4 counts, T-cell response to Vacc-4x and assessment of antibody titer to Vacc-4x peptides and p24, and four vaccine peptides to a non-HIV vaccine antigen (tetanus toxoid antibody titer) as measured from week 21 to week 26.

Study period for part B, Phase II of the trial, was 26 weeks (13 weeks immunization period + 13 weeks follow-up). Twenty four patients were randomized into two groups where one group received Vacc-4x + placebo and one group received Vacc-4x + Revlimid. Patients received six cycles of Vacc-4x vaccination with Revlimid or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26 (study end).

During treatment period all patients remained on ART and received six immunizations (four primary immunizations and two booster immunizations) at weeks 1, 2, 3 and 4 and booster immunizations at weeks 12 and 13 with either Vacc-4x +lenalidomide or placebo over a 13 week period. Key endpoints were observed at week 13 and at week 26 (study end). The patients received lenalidomide or placebo two days prior and on each day of vaccination.

One serious adverse event reported (SAE) in this study was a case of subcutaneous abscess that appeared 45 days after the patient was vaccinated. The SAE was evaluated and classified as unrelated by study investigators. The overall clinical and laboratory tolerance profile was satisfactory.

Further details of the study are available on www.clinicaltrials.gov (NCT01704781).

About the Bionor Pharma Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.

More information about Bionor Pharma is available at www.bionorpharma.com .

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Bionor Pharma ASA CEO Anker Lundemose Tel +47 23 01 09 60 CFO Synne H Roine Tel +47 99 22 98 92

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 81

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 141

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 47

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 144

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 37

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

ADT Inc. Pricing for Secondary Offering and Share Repurchase

Updated Category News Views 210

ADT Inc. Moves Forward with Secondary Public Offering ADT Inc. (NYSE: ADT) has made waves in the financial world by announcing the pricing of a secondary public offering. This significant event involves 56 million shares of common stock that are being sold by certain entities associated with Apollo Global Management, Inc. The process is designed to provide liquidity and...

Continue Reading
Exciting Updates from illumin Holdings Regarding Q2 2025 Results

Updated Category News Views 176

Upcoming Financial Results Announcement Toronto and New York - illumin Holdings Inc. (TSX: ILLM, OTCQB: ILLMF), renowned in the digital advertising technology sector, is gearing up to present its second quarter 2025 financial outcomes. These results are set to be unveiled before market operations commence on an announced date. Join Us for the Live Webcast All interested...

Continue Reading
Exploring Growth in the Mining Remanufacturing Sector

Updated Category News Views 168

Understanding the Mining Remanufacturing Components Market This comprehensive analysis provides insights into the growth of the mining remanufacturing components market. It highlights the increasing demand for sustainable practices, innovations, and market dynamics. Market Size and Growth Rate The mining remanufacturing components market was valued at around US$ 4.20...

Continue Reading
Novo Nordisk's Wegovy Trial Success: Weight Loss Breakthrough

Updated Category News Views 787

Groundbreaking Results from Novo Nordisk's Wegovy® Trial The latest findings from Novo Nordisk indicate a significant breakthrough in weight management through the higher dose of Wegovy, which has delivered an impressive average weight loss of 21% for individuals suffering from obesity. The trial results, presented at a prominent diabetes conference, revealed that...

Continue Reading
Builders FirstSource Announces Leadership Transition Plans

Updated Category News Views 230

Leadership Changes at Builders FirstSource Builders FirstSource, Inc. (NYSE: BLDR) is undergoing a major leadership shift as part of a planned transition. The company has announced that Peter Jackson, who currently serves as the Chief Financial Officer, will step into the role of President and Chief Executive Officer. This change marks an important milestone in the...

Continue Reading